NEXT GENERATION CONDOM CONTRACEPTION TO TACKLE SEXUALLY TRANSMITTED DISEASES & UNINTENDED PREGNANCIES
CASE STUDY (Filmed October 2023, June 2024)
Eudaemon Technologies
Australia
Eudaemon Technologies, an early-stage medtech company with a focus on sexual reproductive health, is developing a hydrogel condom to address the need for a better feeling, next generation condom, with the potential to improve user experience and address issues with traditional latex condoms.
“Over 1 million STI’s being diagnosed every day and up to 120 million unplanned pregnancies every year result in a $60 billion health burden across the globe”, says Co-Founder and Executive Director of Operations, Dr Simon Cook.
Formed in 2018, the company focuses on developing tough hydrogels as an alternative to address issues with odour, colour, and taste commonly associated with latex condoms. This technology can be loaded with small molecule drugs for flavours or anti-STI compounds, and was developed in response to a grant from the Bill and Melinda Gates Foundation to address unplanned pregnancies and STIs.
In 2022 Eudaemon Technologies was awarded AUD$1.5m in funding to advance the clinical trial of their next generation condom project, awarded by the Medical Research Future Fund (MRFF) funding from the Australian Government’s Clinical Translation and Commercialisation Medtech (CTCM) program, delivered by MTPConnect, and supported by MTAA.
Also, funding has come from NSW Health and The Office for Health and Medical Research.
According to Executive Chairman and Co-Founder Nick Northcott, the company has made significant progress in the past six months, including completing a pilot clinical trial involving 35 couples and achieving a major milestone.
“The completion of this Pilot Clinical Trial is a major milestone and value inflection point for the company. The Pilot Clinical data provides strong signal for safety, efficacy and consumer preference for Eudaemon’s Hydrogel Condom platform. We are now poised to move through scaling up our manufacturing, completing a Pivotal Clinical Trial prior to regulatory submission and then entering the market and commercialisation. A very exciting time for Eudaemon Tech as an Australian MedTech manufacturer.”, says Northcott.
Eudaemon Technologies is now focused on scaling up production and obtaining regulatory approval for commercialisation of their high-quality condoms. Once granted approval, the company is working towards scaling their manufacturing to produce the millions of units, with the ultimate aim to manufacture into the billions of high-quality condoms.
Eudaemon Technologies’ vision goes beyond the creation of a superior condom, as the company is ultimately contributing to an important global health cause. By assisting individuals in overcoming barriers to the consistent use of condoms through material innovation, the company endeavours to positively impact public health by mitigating the spread of STIs and reducing unplanned pregnancies on a global scale
-
Newborn screening for congenital hypothyroidism
Assoc Prof Jack is passionate about the health and wellbeing of children and adolescents, with diverse research areas including the impacts of family friendly workplace initiatives, screening and management of thyroid disorders in infants and children. She supports her First Nations colleagues on Indigenous-led research projects funded by the Medical Research Future Fund, aiming to improve the social and emotional wellbeing of First Nations Children. Through her clinical and academic roles, Assoc Prof Jack hopes to make a positive difference to the health and well-being of children and their families.
-
Benefits of prehabilitation ahead of surgery
Dr Matthew Wallen PhD, AES, AEP is a Senior Research Fellow in Cancer Survivorship, the Deputy Lead of the Cancer Survivorship Program, and a Senior Lecturer in Exercise Science and Clinical Exercise Physiology within the College of Nursing and Health Sciences at Flinders University, in South Australia. His clinical interest focuses on improving outcomes for people requiring major surgery, specifically (1) lifestyle interventions, including exercise, nutritional, and psychological support to improve the health and wellbeing of people prior to surgery, termed ‘prehabilitation’, (2) novel physical function assessments aimed at identifying people at risk of treatment-related complications, and (3) implementation of new models of care in cancer.
-
Biological interactions of extracellular vesicles
Raluca Ghebosu graduated from the University of Queensland with a Bachelor of Arts/Bachelor of Science with majors in Japanese and Biomedical Science (2018-2021). She then completed her Bachelor of Science (Honours) with the School of Biomedical Sciences at the University of Queensland in 2022, before pursuing a PhD with A/Prof. Joy Wolfram at the Australian Institute for Bioengineering and Nanotechnology.
